Person: ONSUN, NAHIDE
17 results
Search Results
Now showing 1 - 10 of 17
Publication Metadata only Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: A 48-week comparative study.(2021-03-11T00:00:00Z) Onsun, Nahide; Akaslan, Tahsin Çağdaş; Sallahoglu, Kadriye; Gülcan, Aliye Sevdem; Bulut, Huri; Yabacı, AYŞEGÜL; ONSUN, NAHIDE; YABACI TAK, AYŞEGÜLPublication Metadata only Adult Langerhans Cell Histiocytosis with Recurrent Vulvar Ulcers(2020-01-01T00:00:00Z) EMİROGLU, NAZAN; DİZMAN, DİDEM; CENGİZ, FATMA PELİN; GEÇER, MELİN; ONSUN, NAHİDE; CENGİZ, FATMA PELIN; GEÇER, MELİN; ONSUN, NAHIDEPublication Open Access Which dermatology patients attend to Dermatology Outpatient Clinics during the SARS-CoV-2 outbreak in Turkey and what happened to them?(2020-05-11T04:00:00Z) CENGİZ, Fatma Pelin; EMİROĞLU, Nazan; BAHALI, ANIL GÜLSEL; DİZMAN, DİDEM; TAŞLIDERE, NAZAN; MERT, Ömer; Akarslan, Tahsin Cagdas; Gunes, Begum; KÜÇÜK, Özlem Su; ONSUN, Nahide; CENGİZ, FATMA PELIN; EMİROĞLU, NAZAN; BAHALI, ANIL GÜLSEL; DİZMAN, DİDEM; TAŞLIDERE, NAZAN; GÜNEŞ, BEGÜM; MERT, ÖMER; SU KÜÇÜK, ÖZLEM; ONSUN, NAHIDECoronavirus disease, first emerged in Wuhan, rapidly spread all over the world since December 2019. There are concerns about elective dermatology appointments and its results. Herein, we aimed to find out which type of dermatologic patients attended to dermatology outpatient clinic. The patients visiting the clinics for elective dermatologic diseases between March 11 and 18, 2020, were included in this study. Their age, sex, diagnosis of disease, requirement for emergent intervention, and their medical records about COVID-19 were obtained. There were 390 patients attending to the dermatology outpatient clinic in this period. The most common disease was acne (N: 94, 24%), only 19% of patients need emergent interventions or dose adjustment. There were 40 (10%) patients over the age of 65. After their visits, five patients were diagnosed as COVID-19 in 2weeks. Dermatologic examinations may be a vector for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission since being closed to the patient. Five of our patients were diagnosed as COVID-19 after their elective visit to hospital. Since the asymptomatic course of some young patients, most of our patients were not screened for COVID-19. Our findings support the concerns of elective physician examinations.Publication Open Access A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report(2021-01-01T00:00:00Z) ONSUN, Nahide; KAYA, GÖKHAN; IŞIK, BENGİSU GÜÇKAN; GÜNEŞ, BEGÜM; ONSUN, NAHIDE; KAYA, GÖKHAN; IŞIK, BENGİSU GÜÇKAN; GÜNEŞ, BEGÜMCoronoVac is a non-viable vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nowadays, there has been vaccination program for at-risk groups and older adults in Turkey. We here present 72-year-old male psoriasis patient who developed generalized pustular psoriasis flare after administration of CoronoVac. The COVID-PCR test was negative and investigations for flare etiology were all normal. He was first (to the best of our knowledge) psoriasis patient who developed an erythrodermic flare after the first dose of CoronaVac vaccine.Publication Open Access Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center(2020-12-01T00:00:00Z) GÜNEŞ, BEGÜM; ONSUN, Nahide; YABACI, AYŞEGÜL; ONSUN, NAHIDE; GÜNEŞ, BEGÜM; YABACI TAK, AYŞEGÜLThere have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated.Publication Metadata only Demographic characteristics, treatment, and outcome of patients with Kaposi sarcoma: Ten-year follow-up results of a single center(2021-09-01T00:00:00Z) GÜNEŞ, BEGÜM; MERT, Ömer; ONSUN, Nahide; GÜNEŞ, BEGÜM; MERT, ÖMER; ONSUN, NAHIDEBackground Clinical features, types of Kaposi sarcoma, and treatment outcomes have not been well-defined in Turkey. In this study, we reviewed records of the patients who had been diagnosed with Kaposi sarcoma in the last decade in a single center and evaluated treatment results. Methods Medical records of the Kaposi sarcoma patients seen in the last decade in a single tertiary center were evaluated in detail. Results A total of 27 patients were identified; 18 patients had been checked for HHV8; and 16 of those patients were positive for HHV8. One patient was positive for HIV. Two patients having mycosis fungoides and myasthenia graves developed iatrogenic KS after immunosuppressive treatments. Interferon alpha was used in 21 patients; 8 patients achieved complete response; and 11 patients achieved a partial response. No serious side effects were observed. Systemic involvement did not develop in any patients except lymph node involvement in a patient with widespread skin lesions.Publication Metadata only Do nonobese patients with Behcet-s disease have insulin resistance?(2021-06-01T00:00:00Z) KAHRAMAN, FİLİZ CEBECİ; Kayatas, Kadir; Erdogan, Sevil Savas; ONSUN, Nahide; ONSUN, NAHIDEBackground Some studies have investigated the relationship between Behcet-s disease (BD) and insulin resistance; however, since they did not exclude obese patients from their sample, it remains unclear whether BD itself causes insulin resistance independently of obesity.Publication Metadata only Challenges in early diagnosis of primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma: a case series of four patients.(2020-08-01T00:00:00Z) Akaslan, TÇ; Dizman, D; Emiroğlu, N; Tosuner, Z; Çetin, G; Demirkesen, C; ONSUN, NAHIDE; YILDIZ, PELİN; ÇETİN, GÜVENBackground: Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (AECTCL) is a rare and aggressive lymphoma characterised by ulcerated lesions and a poor prognosis. Objectives: To present a case series of four previously misdiagnosed AECTCL patients and discuss the importance of early diagnosis. Materials and methods: All patients in this study were identified from the database of the Dermatology Department of the Medical School of Bezmialem Vakif University, based on clinical and histopathological diagnosis of AECTCL between 2010 and 2018. Results: AECTCL cases may mimic many benign dermatoses and accurate diagnosis may be delayed. Conclusion: Because of its poor prognosis, early diagnosis of AECTCL may be helpful in improving the likelihood of patient survival, but further study is needed to address the challenges in diagnosing this rare and aggressive lymphoma.Publication Metadata only A'dan Z'ye Kaposi Sarkomu(Galenos Yayın Evi, 2023-03-01) Onsun N. (Editör); ONSUN, NAHIDEPublication Metadata only Cyclosporine(2022-01-01T00:00:00Z) ONSUN, Nahide; ONSUN, NAHIDECyclosporine is an immunosuppressive agent used in the treatment of psoriasis. It shows its action through calcineurin inhibition and T-lymphocytes. With its rapid effect, it can be used as an induction therapy in plaque, pustular and erythrodermic psoriasis. Its most common side effects are elevated serum creatinin values and arterial hypertension. In long-term treatment not to exceed 2 years, it may be used under nephrology control.